WeTrials
Recruiting

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

What is this study?

This study is testing a new experimental cancer drug called VT3989, either by itself or mixed with other standard cancer treatments. Researchers want to find the safest and most effective dose for people with advanced solid tumors or mesothelioma.

Who can participate?

You might qualify if you have advanced solid tumors or mesothelioma that has not responded well to standard treatments. Participants must also have generally healthy organ function and measurable tumors.

What will happen?

You will receive the study medication, VT3989, taken by mouth once a day, and possibly other approved cancer therapies. Your medical team will closely monitor your health, side effects, and how your tumor responds through regular check-ups and lab tests.

Where and when?

This study is currently recruiting patients and is taking place at medical centers in major cities including San Francisco, Chicago, and Boston. Your study doctor can provide the exact location details closest to you.

Key Points
  • 1Testing a new experimental drug named VT3989 for advanced cancers
  • 2Open to patients with specific solid tumors or mesothelioma
  • 3Currently recruiting participants at select locations across the United States

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumor, AdultMesotheliomaNSCLC

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.